

Table 4 continued

S. no.	District	Institutions
168	Kyushu and Okinawa	Oita University Hospital
169	Kyushu and Okinawa	Hospital, University of the Ryukyus
170	Kyushu and Okinawa	Okinawa Prefectural Nanbu Medical Center and Children's Medical Center
171	Kyushu and Okinawa	Kagoshima City Hospital
172	Kyushu and Okinawa	Kagoshima University Medical And Dental Hospital
173	Kyushu and Okinawa	National Hospital Organization Kumamoto Medical Center
174	Kyushu and Okinawa	Kumamoto university hospital
175	Kyushu and Okinawa	Japanese Red Cross Kumamoto Hospital
176	Kyushu and Okinawa	Saga University Hospital
177	Kyushu and Okinawa	Nagasaki University Hospital
178	Kyushu and Okinawa	Kitakyushu Municipal Medical Center
179	Kyushu and Okinawa	Center for Pediatric Emergency Medicine Kitakyushu Municipal Yahata Hospital
180	Kyushu and Okinawa	Kurume University Hospital
181	Kyushu and Okinawa	University Hospital of Occupational and Environmental Health
182	Kyushu and Okinawa	Kyushu University Hospital
183	Kyushu and Okinawa	National Hospital Organization Kyushu Cancer Center
184	Kyushu and Okinawa	Fukuoka University Hospital
185	Kyushu and Okinawa	University of Miyazaki Hospital
186	Kyushu and Okinawa	Sasebo Municipal General Hospital
187	Kyushu and Okinawa	General Hospital Hamanomachi

References

- The Research Program for the Treatment of Chronic Pediatric Diseases of Specified Categories: Department of Health Policy. Available from URL: <http://www.nch.go.jp/policy/shoumann.htm>. Accessed October, 2012.
- Research group of the Treatment of Chronic Pediatric Diseases of Specified Categories. Available from URL: <http://www.aiiku.or.jp/aiiku/mch/syoman/syo.html>. Accessed October, 2012.
- Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. *Jpn J Clin Oncol.* 2012;42(2):139–47.
- Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: a trend or a chance? *J Pediatr.* 1997;130(4):557–60.
- The Committee of the Japan Children's Cancer Registry. The Japan Children's Cancer Registry: outline, results, and perspectives. In: Watanabe S, Tominaga S, Kakizoe T, editors. *Cancer Treatment and survival*. Tokyo: CRC Press; 1995.
- Ajiki W, Hanai A, Tsukuma H, Hiyama T, Fujimoto I. Incidence of childhood cancer in Osaka, Japan, 1971–1988: reclassification of registered cases by Birch's scheme using information on clinical diagnosis, histology and primary site. *Jpn J Cancer Res.* 1994;85(2):139–46.
- Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. *Leukemia.* 2010;24(2):255–64.
- Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. *J Clin Oncol.* 2012;30(14):1663–9.
- Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. *Leukemia.* 2010;24(2):406–18.
- Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. *Leukemia.* 2010;24(2):265–84.
- Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. *Leukemia.* 2010;24(2):345–54.
- Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). *Lancet Oncol.* 2009;10(10):957–66.
- Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: update on prognostic factors. *Curr Opin Pediatr.* 2009;21(1):1–8.
- Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? *Blood.* 2012;120(6):1165–74.
- Disease Registry Committee for the Japanese Society of Pediatric Hematology. *Annual Report of Nationwide Survey 2008*. *Jpn J Pediatr Hematol.* 2009;23:213–9.
- Disease Registry Committee for the Japanese Society of Pediatric Hematology. *Annual Report of Nationwide Survey 2009*. *Jpn J Pediatr Hematol.* 2010;24:182–9.

17. Disease Registry Committee for the Japanese Society of Pediatric Hematology. Diagnostic guidelines for hematological diseases. *Jpn J Pediatr Hematol*. 2009;21 Suppl 5/6:1–76.
18. Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. *Cancer Treat Rev*. 2003;29(1):31–44.
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin*. 2009;59(4):225–49.
20. Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. *Eur J Cancer*. 2006;42(13):2019–36.
21. Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. *Br J Haematol*. 2012;159(3):259–76.
22. Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. *J Clin Oncol*. 1993;11(6):1046–54.
23. Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. *Blood*. 2001;98(6):1714–20.
24. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. *Blood*. 2001;97(1):56–62.
25. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. *J Clin Oncol*. 2009;27(24):4007–13.
26. Imaizumi M, Tawa A, Hanada R, Tsuchida M, Tabuchi K, Kigasawa H, et al. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. *Br J Haematol*. 2011;152(1):89–98.
27. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. *J Clin Oncol*. 2007;25(34):5442–7.
28. Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003–06 from the Japan Association of Childhood Leukaemia Study. *Br J Haematol*. 2012;159(2):204–10.
29. Koga Y, Kumagai M, Takimoto T, Mimaya J, Nakazawa A, Horibe K, et al. Retrospective analysis of 157 patients with pediatric Hodgkin lymphoma in Japan: investigation by four pediatric cancer study groups. *Rinsho Ketsueki*. 2012;53(4):443–9.
30. Manipadam MT, Nair S, Viswabandya A, Mathew L, Srivastava A, Chandy M. Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India. *World J Pediatr*. 2011;7(4):318–25.
31. Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children's Cancer Study Group. *J Clin Pathol*. 1997;50(2):128–34.
32. Spitz MR, Sider JG, Johnson CC, Butler JJ, Pollack ES, Newell GR. Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973–82. *J Natl Cancer Inst*. 1986;76(2):235–9.
33. Percy CL, Smith MA, Linet M, Gloeckler Ries LA, Friedman DL. Lymphoma and reticuloendothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG, et al., eds. *Cancer incidence and survival among children and adolescents. United States SEER Program 1975–1995*. Bethesda, MD: National Cancer Institute, SEER Program, 1999;35–49. Available at: <http://www.acco.org/LinkClick.aspx?fileticket=CGsKkVhAH1Y%3D&tabid=670>. Accessed November, 2012.
34. Fujita N, Kobayashi R, Takimoto T, Nakagawa A, Ueda K, Horibe K. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. *Leuk Lymphoma*. 2011;52(2):223–9.
35. Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, et al. Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol. *Leuk Lymphoma*. 2008;49(4):757–62.
36. Tsurusawa M, Katano N, Hirota T, Ito M, Yanase T, Asami K, et al. Studies of childhood non-Hodgkin's lymphoma-treatment results with the CCLSG NHL 960 protocol. *Children's Cancer and Leukemia Study Group (CCLSG)*. *Rinsho Ketsueki*. 1998;39(11):1092–8.
37. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. *Blood*. 1999;94(10):3294–306.
38. Bhatia S, Nesbit ME Jr, Egeler RM, Buckley JD, Mertens A, Robison LL. Epidemiologic study of Langerhans cell histiocytosis in children. *J Pediatr*. 1997;130(5):774–84.
39. Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. *Cancer*. 2006;107(3):613–9.
40. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. *Int J Hematol*. 2007;86(1):58–65.
41. Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, et al. Chemotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. *Blood*. 2011;118(17):4577–84.
42. Kikuchi A, Hasegawa D, Ohtsuka Y, Hamamoto K, Kojima S, Okamura J, et al. Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study. *Br J Haematol*. 2012;158(5):657–61.
43. Hasegawa D, Manabe A, Yagasaki H, Ohtsuka Y, Inoue M, Kikuchi A, et al. Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99). *Pediatr Blood Cancer*. 2009;53(6):1011–5.
44. Yoshida N, Hirabayashi S, Watanabe S, Zaike Y, Tsuchida M, Yoshimi A, et al. Prognosis of 75 patients with juvenile myelomonocytic leukemia: prospective study by MDS committee in the Japanese Society of Pediatric Hematology. *Rinsho Ketsueki*. 2011;52(12):1853–8.

厚生労働科学研究費補助金
難治性疾患克服研究事業

「一過性骨髄異常増殖症の病態解明と
診断・治療法の確立に関する研究」

平成25年度

発行：平成26年3月

発行者：林泰秀（研究代表者）

事務局：群馬県立小児医療センター

〒377-8577 群馬県渋川市北橘町下箱田779番地

TEL:0279-52-3551 FAX:0279-52-2045

